<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02626234</url>
  </required_header>
  <id_info>
    <org_study_id>CINC280A2105</org_study_id>
    <nct_id>NCT02626234</nct_id>
  </id_info>
  <brief_title>A Drug-drug Interaction (DDI) Study to Assess the Effect of INC280 on the Pharmacokinetics of Digoxin and Rosuvastatin in Patients With cMET-dysregulated Advanced Solid Tumors</brief_title>
  <official_title>A Phase I, Multicenter, Open-label, Single-sequence Drug-drug Interaction Study to Assess the Effect of INC280 on the Pharmacokinetics of Digoxin and Rosuvastatin in Patients With cMET-dysregulated Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      the study aim to assess the effect of INC280 on the pharmacokinetics of digoxin and
      rosuvastatin in patients with cMET-dysregulated advanced solid tumors
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 8, 2015</start_date>
  <completion_date type="Actual">April 28, 2017</completion_date>
  <primary_completion_date type="Actual">February 28, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUClast of digoxin and rosuvastatin</measure>
    <time_frame>Up to 240 hours post digoxin and rosuvastatin dose</time_frame>
    <description>digoxin and rosuvastatin pharmacokinetics parameters</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCinf of digoxin and rosuvastatin</measure>
    <time_frame>Up to 240 hours post digoxin and rosuvastatin dose</time_frame>
    <description>digoxin and rosuvastatin pharmacokinetics parameters</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lambda_z of digoxin and rosuvastatin</measure>
    <time_frame>Up to 240 hours post digoxin and rosuvastatin dose</time_frame>
    <description>digoxin and rosuvastatin pharmacokinetics parameters</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of digoxin and rosuvastatin</measure>
    <time_frame>Up to 240 hours post digoxin and rosuvastatin dose</time_frame>
    <description>digoxin and rosuvastatin pharmacokinetics parameters</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax of digoxin and rosuvastatin</measure>
    <time_frame>Up to 240 hours post digoxin and rosuvastatin dose</time_frame>
    <description>digoxin and rosuvastatin pharmacokinetics parameters</description>
  </primary_outcome>
  <primary_outcome>
    <measure>T1/2 of digoxin and rosuvastatin</measure>
    <time_frame>Up to 240 hours post digoxin and rosuvastatin dose</time_frame>
    <description>digoxin and rosuvastatin pharmacokinetics parameters</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CL/F of digoxin and rosuvastatin</measure>
    <time_frame>Up to 240 hours post digoxin and rosuvastatin dose</time_frame>
    <description>digoxin and rosuvastatin pharmacokinetics parameters</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vz/F of digoxin and rosuvastatin</measure>
    <time_frame>Up to 240 hours post digoxin and rosuvastatin dose</time_frame>
    <description>digoxin and rosuvastatin pharmacokinetics parameters</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events based on the CTCAE v4.03 grade (severity) and other safety data (e.g.,ECG, vital signs, laboratory results)</measure>
    <time_frame>From consent to 30 days post last dose</time_frame>
    <description>To assess safety and tolerability of INC280 in patients with cMET-dysregulated advanced solid tumors</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate of patients treated with INC280</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Overall response rate is defined as Complete Response and Partial Response calculated per RECIST 1.1, per investigator assessment from Day 1 until date of progression or death whichever comes first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate of patients treated with INC280</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Disease control rate is defined as calculated as the proportion of patients with best overall response of Complete Response, Partial Response, or Stable Disease calculated per RECIST 1.1, per investigator assessment from Day 1 until date of progression or death whichever comes first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of INC280 during DDI phase</measure>
    <time_frame>Day 22, Cycle 2 Day 1</time_frame>
    <description>INC280 concentrations collected on Day 22 during DDI phase and Cycle 2 Day 1 during post DDI phase along with a listing of individual values.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>cMET-dysregulated Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>INC280</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INC280</intervention_name>
    <arm_group_label>INC280</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>digoxin</intervention_name>
    <arm_group_label>INC280</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rosuvastatin</intervention_name>
    <arm_group_label>INC280</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients must have:

          -  advanced solid tumors and have confirmed cMET dysregulation

          -  at least one measurable lesion as defined by RECIST 1.1.

          -  recovered from all toxicities related to prior anti-cancer therapies

          -  adequate organ function

          -  ECOG performance status (PS) of 0 or 1

        Exclusion Criteria:

        Patients must not have:

          -  known hypersensitivity to any of the excipients of INC280

          -  prior treatment with cMET or HGF-targeting inhibitor

          -  known hypersensitivity to digoxin or rosuvastatin or its excipients

          -  symptomatic central nervous system (CNS) metastases who are neurologically unstable

          -  presence or history of carcinomatous meningitis

          -  history of another primary malignancy that is currently clinically significant or
             currently requires active intervention

          -  Clinically significant, uncontrolled heart diseases, including QTcF ≥ 450 msec (male
             patients), ≥ 460 msec (female patients) on the screening ECG

          -  Thoracic radiotherapy to lung fields ≤ 4 weeks prior to starting INC280

          -  Major surgery within 4 weeks prior to starting INC280

          -  Patients receiving unstable or increasing doses of corticosteroids.

          -  Impairment of GI function or GI disease that may significantly alter the absorption of
             INC280

          -  Patients who have received, or are expected to receive digoxin or rosuvastatin within
             21 days prior to the beginning of the DDI phase (Day 1) and for the duration of the
             DDI phase.

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Emory University School of Medicine/Winship Cancer Institute Phase 1 Working Group</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dartmouth Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vienna</city>
        <zip>A-1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Brno</city>
        <zip>65653</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ioannina</city>
        <state>GR</state>
        <zip>455 00</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Athens</city>
        <zip>18547</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Candiolo</city>
        <state>TO</state>
        <zip>10060</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Majadahonda</city>
        <state>Madrid</state>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>London</city>
        <zip>W1G 6AD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Manchester</city>
        <zip>M20 9BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Czechia</country>
    <country>Greece</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 13, 2015</study_first_submitted>
  <study_first_submitted_qc>December 7, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 10, 2015</study_first_posted>
  <last_update_submitted>December 21, 2017</last_update_submitted>
  <last_update_submitted_qc>December 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cMET, INC280, rosuvastatin, digoxin</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
    <mesh_term>Digoxin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

